Results 101 to 110 of about 1,579,650 (291)
ABSTRACT Methane's efficient catalytic removal is vital for sustainable development. Bimetallic catalysts, though promising for methane activation, pose a design challenge due to their complex compositional space. This work introduces an integrated framework that combines high‐throughput density functional theory (DFT) and interpretable machine ...
Mingzhang Pan +8 more
wiley +1 more source
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley +1 more source
The CXCL5/CXCR2 axis directly inhibits ferroptosis in ICC cells by activating the NF‐κB/PTGS2 pathway. Meanwhile, the CXCL5/CXCR2 axis recruits N2 TANs, and the activated PTGS2 promotes the secretion of TNF‐α from the recruited N2 TANs via the CCL2/CCL7/CCR2 pathway, thereby activating the NF‐κB/PTGS2 axis and forming a positive feedback loop, which ...
Chanqi Ye +17 more
wiley +1 more source
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma).
Ruo Qiao Chen +6 more
doaj +1 more source
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu +7 more
wiley +1 more source
Immune checkpoint blockade (ICB) therapy targeting PD-L1 via monoclonal antibody (mAb) has shown extensive clinical benefits in the diverse types of advanced malignancies. However, most patients are completely refractory to ICB therapy owing to the PD-L1
Youngjoo Lee +9 more
doaj +1 more source
PD-L1+ virions can be produced from PD-L1+ CD4 T cells or monocyte-derived macrophages in vitro.
Activated CD4 T cells or MDM from HIV-uninfected individuals (N = 7) were exposed or not to HIV lab-derived variants in presence or in absence of emtricitabin.
Riddhima Banga (634344) +11 more
core +1 more source
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo +10 more
wiley +1 more source
PD-L1 Status in Refractory Lymphomas - Fig 2
(A): Hematoxylin and Eosin (H&E) slide of a case of lymphocyte depleted variant of classical Hodgkin lymphoma (cHL); (B): The tumor cells were diffusely (100%) and strongly (3+) positive for PD-L1 protein by immunohistochemistry (clone: SP142); (C-D ...
Jeffery Kimbrough (3353009) +8 more
core +1 more source
Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering [PDF]
Hovedbudskap: Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro +2 more
core

